As of Feb 23
| -0.25 / -0.99%|
The 9 analysts offering 12-month price forecasts for Acorda Therapeutics Inc have a median target of 23.00, with a high estimate of 60.00 and a low estimate of 22.00. The median estimate represents a -8.00% decrease from the last price of 25.00.
The current consensus among 10 polled investment analysts is to Hold stock in Acorda Therapeutics Inc. This rating has held steady since February, when it was downgraded from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.